DR REDDYS LABORATORIES LTD (RDY) Stock
5 of the hedge funds AlphaScala tracks reported RDY in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $106.46M.
Which hedge funds own RDY?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 7.35M | $106.46M | -7% |
| Marshall Wace | 2.03M | $29.35M | -24% |
| Millennium Management Israel Englander | 468K | $6.79M | +721% |
| D.E. Shaw David Shaw | 127K | $1.83M | -9% |
| Citadel Ken Griffin | 79K | $1.15M | -82% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →RDY price chart
Powered by TradingViewWhat does DR REDDYS LABORATORIES LTD do?
Dr. Reddy's Laboratories Ltd. is a prominent pharmaceutical company, engaged in the research, development, manufacturing, and marketing of a wide array of generic medicines, active pharmaceutical ingredients (APIs), and biosimilars. Founded in 1984, the company plays a critical role in providing affordable healthcare solutions on a global scale. Dr. Reddy's Laboratories is known for its robust product portfolio that extends across various therapeutic areas, including oncology, gastroenterology, cardiovascular, and dermatology. The company's global footprint spans both emerging markets and developed economies, allowing it to serve diverse patient populations and adhere to different regulatory landscapes. In the financial markets, Dr. Reddy's Laboratories is significant due to its contribution to the healthcare sector, providing alternatives to high-priced medications and promoting access to essential drugs. As part of its commitment to addressing health challenges, the company invests heavily in research and innovation to meet the evolving needs of patients worldwide. Dr. Reddy's not only impacts the pharmaceutical industry but also contributes to the broader life sciences market with its focus on sustainability and compliance with international quality standards.